NovoCure Ltd (NVCR)
- Sector
- Health Care
- Last price
- $14.17
- As of
Kresmion compiles this page from NVCR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
NovoCure Ltd (NVCR): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-01.
See the full NVCR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NVCR on one page. Preview it with sample data, then open it live with a free account.
Preview the NVCR dossierActive events for NVCR
- high13F: funds added
4 tracked funds increased NVCR this 2026Q2, institutional consensus
- high13F: large reduction
CITADEL ADVISORS LLC cut 82% of NVCR (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +85% to NVCR (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +205% to NVCR (2026Q2)
- high13F: large increase
D. E. Shaw & Co., Inc. added +58% to NVCR (2026Q2)
FREE, NO ACCOUNT
Every event on NVCR, as it fires
You are seeing 5 of 14 events recorded on NVCR since 2026-05-31.
The five above landed across 2 days. The other 9 were recorded on 3 other days. 8 of the 14 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NVCR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP G6674U108 · 2026Q2 | $29.6M | 0.04% | , |
| D. E. Shaw & Co., Inc.CUSIP G6674U108 · 2026Q2 | $15.5M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP G6674U108 · 2026Q2 | $12.2M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP G6674U108 · 2026Q2 | $4.2M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP G6674U108 · 2026Q2 | $2.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP G6674U108 · 2026Q2 | $321K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NVCR
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NVCR against its peers
NVCR's operating margin of -23.5% ranks in the 10th percentile of 25 Health Care sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-01-02.
| Metric | NVCR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 655M USD | 912M USD | 37 | 25 |
| Gross margin | 74.5% | 59.9% | 81 | 17 |
| Operating margin | -23.5% | 5.0% | 10 | 25 |
| Net margin | -20.8% | 0.2% | 10 | 25 |
| Return on equity | -40.0% | 2.4% | 14 | 24 |
| P / E | n/a | 40.7x | n/a | 12 |
Peers (25): OMCL, ALHC, CERT, ATEC, AMN, PNTG, XRAY, LMAT, WGS, CNMD, TNDM, SEM.D, INSP, PGNY, USPH, TDOC, STAA, GDRX, OMDA, TMDX, MD, PRCT, BKD, IRMD, HSTM. Fiscal periods ending between 2025-12-31 and 2026-01-02. Every figure is one full fiscal year read from one annual filing (NVCR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow NVCR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to NVCR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.